WHO ICTRP trial
The safety and efficacy of etelcalcetide for the treatment of secondary…
JPRN-UMIN000027344 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-UMIN000027344 |
|---|---|
| Public title | The safety and efficacy of etelcalcetide for the treatment of secondary hyperparathyroidism compared with cinacalcet |
| Scientific title | The safety and efficacy of etelcalcetide for the treatment of secondary hyperparathyroidism compared with cinacalcet - The safety and efficacy of etelcalcetide compared with cinacalcet |
| Primary sponsor | Matsunami general hospital |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | Patients on maintenance hemodialysis treated with cinacalcet for secondary hyperparathyroidism |
| Interventions | etelcalcetide (5mg - 10mg) every hemodialysis session 6 months |
| Registration date | May 15, 2017 |
| Target size | 10 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: